SOURCE: MagForce Nanotechnologies AG

September 21, 2010 03:06 ET

MagForce Nanotechnologies AG Announces Publication of Clinical Data Using Nanoparticles for the Treatment of Recurrent Glioblastoma Multiforme

BERLIN--(Marketwire - September 21, 2010) -

MagForce Nanotechnologies AG / MagForce Nanotechnologies AG Announces Publication of Clinical Data Using Nanoparticles for the Treatment of Recurrent Glioblastoma Multiforme processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Berlin, September 21, 2010- MagForce Nanotechnologies AG (FSE: MF6) announced today the publication of clinical data from a clinical study examining the safety and efficacy of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy in patients with recurrent glioblastoma multiforme.

The study data, published on September 20, 2010 in the Journal of Neuro-Oncology, is available online on the Journal's website at http://www.springerlink.com/content/u27ll42612302123/ or http://www.ncbi.nlm.nih.gov/pubmed/20845061

"This data publication provides detailed insight into the clinical data that supported our recent regulatory approval for Nano-CancerÒ therapy. Through the publication, we are pleased to address a wider international audience and give them insight into MagForce's novel concept of using nanotechnology for the treatment of cancer," said Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG. "We are currently focused on strengthening our commercialization team and infrastructures in preparation for the next strategic steps, including the planned Q1 2011 product launch in Germany, additional clinical trials, and further internationalization."

Nano-CancerÒ therapy uses iron oxide nanoparticles, which are injected into the tumor and, due to their special coating, aggregate and remain in place. The patient is then placed into a magnetic field applicator. Through the application of an alternating magnetic field, the nanoparticles begin to oscillate, produce warmth, and damage or kill the tumor tissue.

ABOUT MAGFORCE NANOTECHNOLOGIES:

MagForce Nanotechnologies AG is a leader in the area of nanotechnology- based cancer treatment. The proprietary procedure which it has developed, Nano- Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

DISCLAIMER:

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

For questions, please contact:

Stacy Wiedenmann
Director Investor Relations & Corporate Communications
MagForce Nanotechnologies AG
Max-Dohrn-Str. 8
10589 Berlin
T +49 30 308 380 31
F +49 30 308 380 99
M +49 151 12000 722
email: swiedenmann@magforce.com
www.magforce.com


[HUG#1445554]


--- End of Message ---

MagForce Nanotechnologies AG
Max-Dohrn-Str. 8 Berlin  Germany

Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MagForce Nanotechnologies AG via Thomson Reuters ONE

Contact Information